HBV

HBV-IN-6 is a potent inhibitor of HBV (EC50: 287.9 nM).

HBF-0259 is an inhibitors of hepatitis B virus surface antigen (HBsAg) secretion with an EC50 of 11.3 μM and a CC50 value of >50 μM in HepG2.2.15 cells.

HBV-IN-41 (compound 45) is a potent, orally active inhibitor of Hepatitis B Virus (HBV), exhibiting an EC50 value of 0.027μM [1].

Valtorcitabine dihydrochloride, a DNA polymerase inhibitor, is used potentially for the treatment of HBV infection.

HEC72702: New HBV capsid inhibitor, from GLS4. No CYP1A2, CYP3A4, CYP2B6 induction at 10μM.

Ent-Entecavir, an enantiomeric impurity of Entecavir (an oral HBV drug), inhibits HBV replication as a reverse transcriptase inhibitor.

IR415 selectively interacts with Hepatitis B virus X protein (HBx, Kd = 2 nM) and blocks HBV-mediated RNAi suppression, reverses the inhibitory effect of HBx

AB-836, an orally active hepatitis B virus (HBV) capsid inhibitor, hampers viral replication by engaging with the HBV core protein.

Emtricitabine triphosphate tetrasodium salt is the tetrasodium salt form of the phosphorylated anabolite (-)-Emtricitabine triphosphate, an active nucleoside

Carbovir, an NRTI, induces mitochondrial toxicity in human liver cancer cells.

SHR5133 is a potent, orally active regulator of HBV capsid assembly that reduces HBV DNA (EC50: 26.6 nM).

Besifovir Dipivoxil maleate, an oral HBV prodrug (LB80380), suppresses HBV DNA in naive and lamivudine-resistant CHB cases.

HBV-IN-30, a flavone derivative, inhibits cccDNA in HBV research.

HBV-IN-12 is a potent inhibitor of hepatitis B surface antigen (HBsAg).

Lagociclovir valactate is a prodrug of Lagociclovir . Lagociclovir valactate is an orally active anti- HBV agent [1] .

Oxynitidine, an HBV inhibitor (ID50 = 30.8 µg/mL), effectively suppresses HBV DNA replication and may be utilized in viral infection research [1].

HBV-IN-17 (compound 8) is a potent regulator of HBV capsid assembly (EC50: 511 nM).

Tenofovir amibufenamide (HS-10234) 是一种 Tenofovir 前药，是一种具有口服活性的抗病毒化合物。Tenofovir amibufenamide 对乙型肝炎病毒 (HBV)具有抑制作用，可用于慢性乙型肝炎 (CHB) 研究。

ALG-000184, a prodrug of the potent HBV capsid assembly modulator ALG-001075, shows potential for use in HBV infection research.

TLR8 agonist 4 inhibits wild-type and lamivudine/entecavir-resistant HBV; IC50: 0.15 μM and 0.10 μM.

TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (with a lowest effective concentration (LEC) [hTLR7] of 1.6 μM) and TLR8 (LEC [hTLR8] of 1.6 μM). It acts on human peripheral blood mononuclear cells (hPBMC) with agonistic activity (LEC [hPBMC] = 0.5 μM). In mice and cynomolgus monkeys, TLR7/8 agonist 13 induces endogenous IFNα, activates myeloid dendritic cells and monocytes, promoting their differentiation towards a TH1 phenotype. In chronic AAV-HBV mouse models, it reduces viral load and HBV surface antigen levels. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, facilitating the response of HBV antigen-specific CD8 T cells. This compound is useful for hepatitis B virus research.

HBV-IN19 TFA suppresses HBsAg, hampers HBV infection, and aids in HBV research.

HBV-IN-18 (Compound 3) is an HBV capsid assembly modulator (CpAM) (EC50: 2790 nM).

FNC-TP trisodium, active intracellular FNC form, inhibits NRTI, fights HIV, HBV, and HCV.

HBV-IN-12: strong HBsAg & HBV DNA inhibitor; EC50 0.001-0.05 μM & 0.001-0.02 μM respectively. (WO2021204252A1)

HBV-IN-24 inhibits HBV DNA, HBsAg, HBeAg (EC50: 0.6, 0.6, 4.6 nM), and has antiviral properties with neurotoxicity mitigation.

SAG-524 is a powerful oral small molecule that inhibits HBV viral replication. In HepG2.2.15 cells, SAG-524 reduced HBV-DNA and HbsAg levels in the supernatant with IC₅₀ values of 0.92 nM and 1.4 nM, respectively [1].

CCC-0975 is an inhibitor of hepatitis B virus (HBV) with an EC50 of 10 μM. It interferes with the conversion of relaxed circular DNA (rcDNA) to covalently closed circular DNA (cccDNA) and reduces cccDNA and its precursor deproteinized rcDNA (DP-rcDNA), without promoting their degradation inside cells. CCC-0975 holds potential for chronic hepatitis B research.

HBV/HDV-IN-2 (Compd 143) functions as an inhibitor for HBV, HDV, and PD-1/PD-L1, demonstrating an EC 50 of 35 nM in T cell activation.

HBV-IN-11 is a potent inhibitor of HBsAg secretion (EC50: 0.46 μM).

HBV-IN-31: strong cccDNA inhibitor, anti-HBV, IC50=0.13 µM HBsAg, hampers cell growth.

HBV/HDV-IN-3 (Compd 1) acts as a dual inhibitor for HBV and HDV, demonstrating an efficacy (EC 50) below 50 nM against HBV .

HBV-IN-20 is a potent, orally active HBV inhibitor (EC50: 0.46 μM). HBV-IN-20 is a classical type II CpAM (core protein assembly regulator).